pfizer

Pfizer Spins Off Zoetis, Biggest IPO Since Facebook, Shares Soar

Pfizer's animal health business Zoetis has raised about $2.2 billion in its initial public offering of 86.1 million shares, and the stock is expected to begin trading Friday. Merck & Co.'s fourth-quarter profit fell 7 percent as generic competition slashed sales of its blockbuster allergy drug Singulair.

Pfizer Earnings Help Lift Stocks, Pushing Dow Toward 14,000

Pfizer helped keep the stock market rally alive Tuesday. The drugmaker's stock gained after posting strong earnings, pushing the Dow closer to 14,000. The Standard and Poor's 500 also rose, adding eight points to 1,507.84 points. The Nasdaq composite dropped less than a point to 3,153.66.

Hurricane Sandy Leads Companies to Postpone Earnings Reports

A number of major U.S. companies postponed quarterly earnings reports Monday as Hurricane Sandy bore down on the East Coast and financial markets were closed: Among the biggies waiting until the rain stops: Pfizer, Thomson Reuters, NRG Energy, and Martha Stewart Living Omnimedia.

A Simple Strategy to Boost Your Returns

Options: It's a word that makes you shiver with fear or salivate at opportunity. In fact, there's one options strategy that's almost certain to add some extra money to your portfolio over time, without adding lots of risk. It's the technique known as writing covered calls, and it's perfect for times like this.

Was Dr. Oz's Apple Juice 'Crisis' a Ratings Ploy?

Last week, TV host Dr. Mehmet Oz took on apple juice, declaring that the classic drink may be slowly poisoning America's children with arsenic. But the FDA and the juice companies have credibly refuted his claims. So was Dr. Oz's announcement meant to be a legitimate health warning, or a just cynical attempt to boost ratings?

Big Pharma Ads Flaunt FDA Rules

Officially, it's the FDA's job to ensure that pharmaceutical ads adhere to guidelines. But the agency's annual compliance budget is $9 million, while drug companies spend $58 billion a year on marketing. So it comes as no surprise that only 18% of ads are in compliance with the rules. But it's still disturbing: This is your health.

Which Comes First: Jobs or Profits?

Lots of companies are laying off workers, trying to cut costs and improve their profit margins. But how should investors view the news of job cuts at a company? As a sign of deep trouble and worse to come, or as proof of committed management and better times ahead? Here's how to read the pink slips.

Pfizer Sells Capsugel: Will More Asset Sales Follow?

On Monday, Pfizer announced it would sell its Capsugel business to private-equity firm KKR for $2.375 billion. If the hints the drugmaker has been giving lately are true, the move could be the start of two years of major asset sales. Here's what's ahead for the world's biggest pharmaceutical company.

Next Commerce Chief Will Play Key Role on Exports

This week, President Obama announced that he's nominating Commerce Secretary Gary Locke as U.S. Ambassador to China. There are several short-list contenders to replace Locke at Commerce, but the question is: Who would best be able to help Obama double U.S. exports in the next five years?

Japan Finds No Link Between Vaccines and Child Deaths

Japan's health ministry says it's continuing its suspension of pediatric vaccines made by Pfizer and Sanofi-Aventis, despite finding no direct link between the vaccines and the deaths of four children. Both drugmakers are cooperating with the government and expect to be cleared.

Top-Selling Drugs About to Lose Patent Protection

The pharmaceutical industry is about to fall off a cliff -- a patent cliff. Over the next few years, some of the world's most popular and lucrative medicines will go off patent, and generic competition will siphon an estimated quarter of a trillion dollars from companies' bottom lines. Here's a rundown:

Supreme Court Limits Lawsuits Against Vaccine Makers

Vaccine makers such as Pfizer are breathing easier now that the Supreme Court has ruled they can't be sued for defective vaccine designs. The majority opinion by Justice Antonin Scalia was unequivocal: Congress has barred lawsuits over the rare but unavoidable side effects of vital vaccines.

Big Pharma Looks Beyond Drugs to Smartphone Apps

Pharmaceutical companies looking for fresh sources of profit are increasingly investing in a range of health care innovations that aren't drugs at all, from smartphone apps and educational websites to social media platforms and wireless devices, reports Ernst & Young.

Two Reasons for Clinical Data Shares to Soar Again

From October 2010 to February 2011, biotech Clinical Data's stock doubled, mostly thanks to FDA approval of its novel antidepressant. But also pushing the stock up -- and making it likely to perhaps double again -- is speculation that a Big Pharma will buy Clinical Data.

What's Behind the Share Buyback Binge?

Companies that have piled up cash over the past few years are finding one good use for it: Repurchasing their own shares. January alone saw $57 billion in buybacks, compared with $357 billion for all of 2010. While buybacks don't add value, they do give investors more options.

Two Drugs Found to Fight Steve Jobs' Rare Cancer Type

Pfizer's cancer drug Sutent and Novartis's drug Afinitor have both been found to be effective against the rare form of pancreatic cancer that Apple CEO Steve Jobs was diagnosed with in 2004, according to two studies published in the New England Journal of Medicine.

Pfizer 4Q Earnings Nearly Quadruple

Pfizer beat Wall Street expectations by a slim margin as its profits nearly quadrupled, compared to a 2009 quarter hurt by big restructuring charges.